Liveome

Seoul, South Korea· Est. 2020

South Korean biotech developing precision microbiome diagnostics and therapeutics for metabolic diseases through advanced genomic analysis.

liveome.co.kr

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

South Korean biotech developing precision microbiome diagnostics and therapeutics for metabolic diseases through advanced genomic analysis.

Metabolic

Technology Platform

Proprietary microbiome sequencing and bioinformatics platform that analyzes gut microbial composition and function to identify biomarkers and therapeutic targets for metabolic disorders.

Opportunities

Growing global interest in microbiome-based therapies, high prevalence of metabolic diseases in Asian populations, and potential for diagnostic-therapeutic combinations in personalized medicine.

Risk Factors

Scientific uncertainty in microbiome-disease causality, regulatory challenges for novel microbiome products, and intense competition in the rapidly evolving microbiome therapeutics space.

Competitive Landscape

Competes with Seres Therapeutics, Vedanta Biosciences, and Finch Therapeutics in microbiome therapeutics, and DayTwo in microbiome diagnostics, differentiated by focus on Asian metabolic disease populations and integrated diagnostic-therapeutic approach.

More companies in South Korea →